Project Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 abiraterone abiraterone acetate ADC ADT ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T CD3 clinical trial crispr darolutamide docetaxel drug repurposing drug resistance enzalutamide EZH2 inhibitor HRR immunotherapy mcrpc mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus PARP1 PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data STEAP1 T-cell therapy
Latest Posts
- Phase 3 DASL-HiCaP: Darolutamide Reduces Metastasis Risk in High-Risk Prostate Cancer October 24, 2026
- UPDATE: PROTEUS Substudy Shows Improved Event-Free Survival With Perioperative Apalutamide October 24, 2026
- UPDATE: Bavdegalutamide Shows Stronger Activity in Prostate Cancers With Specific AR Mutations October 23, 2026
- UPDATE: TheraPb Reports 11.2-Month Median rPFS With 212Pb-ADVC001 October 23, 2026
Low-Dose Abiraterone Acetate: Phase 1 Trial Looks Very Promising
/in Clinical Trial, Metastatic, Phase 1/by MaxTaiwanese Study Uncovers Cancer-Fighting Potential of Common Allergy Drug
/in Drug repurposing, Preclinical Research/by MaxSummary of the PC-BETS Substudy C: Darolutamide in Biomarker-Selected mCRPC
/in Clinical Trial, Metastatic, Phase 2/by MaxFinal Data From Phase 3 PSMAfore Trial About 177Lu-PSMA-617 (Pluvicto)
/in Clinical Trial, Metastatic, Phase 3/by MaxEuropean Commission Approves Darolutamide Plus ADT for Metastatic Hormone-Sensitive Prostate Cancer
/in FDA approvals/by MaxThe European Commission has granted marketing authorization to darolutamide (Nubeqa) combined with androgen deprivation therapy (ADT) for treating metastatic hormone-sensitive prostate cancer (mHSPC). This approval, following a positive opinion from the European Medicines Agency in June 2025, allows darolutamide plus ADT to be used with or without docetaxel, offering clinicians greater flexibility in tailoring treatment. […]
Fracture Risk in Prostate Cancer: Insights from a STAMPEDE Trial Analysis on ADT and Zoledronic Acid
/in Retrospective studies/by MaxUpdate About PSMAddition Phase 3 Trial
/in Clinical Trial, Metastatic, Phase 3/by MaxCRISPR: Gene Breakthrough Could Starve Cancer Cells of Vitamin D
/in CRISPR, Preclinical Research/by Max